Icon

Ampio Pharm Stock Analysis and Price Target COMMON STOCK | Biotechnology | NYE

stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.31

+0.02 (+6.31)%

USD 4.53M

0.12M

N/A

N/A

Icon

AMPE

Ampio Pharm (USD)
COMMON STOCK | NYE
USD 0.31
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 4.53M

N/A

USD 0.31

Ampio Pharm Stock Forecast

N/A

Based on the Ampio Pharm stock forecast from 0 analysts, the average analyst target price for Ampio Pharm is not available over the next 12 months. Ampio Pharm’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Ampio Pharm is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Ampio Pharm’s stock price was USD 0.31. Ampio Pharm’s stock price has changed by +2.36% over the past week, +46.90% over the past month and -88.57% over the last year.

No recent analyst target price found for Ampio Pharm
No recent average analyst rating found for Ampio Pharm

Company Overview

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The...Read More

https://www.ampiopharma.com

373 Inverness Parkway, Englewood, CO, United States, 80112

8

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Ampio Pharm (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S +0.65 (+0.41%) USD361.26B 41.20 3.70

ETFs Containing AMPE

Symbol Name AMPE's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About AMPE Stock

Stock Target Advisor's fundamental analysis for Ampio Pharm's stock is Slightly Bearish.

Unfortunately we do not have enough data on AMPE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AMPE's stock to indicate what its average analyst target is.

AMPE stock's Price/Earning ratio is 26.87. Our analysis grades AMPE stock's Price / Earning ratio at F. This means that AMPE stock's Price/Earning ratio is above 70% of the stocks in the Biotechnology sector in the NYE exchange. Based on this AMPE may be a overvalued for its sector.

The last closing price of AMPE's stock was USD 0.31.

The most recent market capitalization for AMPE is USD 4.53M.

Unfortunately we do not have enough analyst data on AMPE's stock to indicate whether its price will go up or not.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...